• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管内皮生长因子刺激慢性淋巴细胞白血病细胞中蛋白激酶 CβII 的表达。

Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells.

机构信息

Division of Haematology, School of Cancer Studies, University of Liverpool, Liverpool, United Kingdom.

出版信息

Blood. 2010 Jun 3;115(22):4447-54. doi: 10.1182/blood-2009-06-229872. Epub 2010 Feb 17.

DOI:10.1182/blood-2009-06-229872
PMID:20164467
Abstract

Chronic lymphocytic leukemia (CLL) is a malignant disease of mature B lymphocytes. We have previously shown that a characteristic feature of CLL cells are high levels of expression and activity of protein kinase CbetaII (PKCbetaII), and that this might influence disease progression by modulating signaling in response to B-cell receptor engagement. The aim of the present work was to investigate the factors involved in stimulating PKCbetaII expression in CLL cells. Here we show that the activation of PKCbetaII in CLL cells stimulated with vascular endothelial growth factor (VEGF) can drive expression of the gene for PKCbeta, PRKCB1. We found that this effect of VEGF on PRKCB1 transcription is paralleled by high expression of PKCbetaII protein and therefore probably contributes to the malignant phenotype of CLL cells. Taken together, the data presented in this study demonstrate that VEGF, in addition to its role in providing prosurvival signals, also plays a role in overexpression of PKCbetaII, an enzyme with a specific pathophysiologic role in CLL.

摘要

慢性淋巴细胞白血病(CLL)是一种成熟 B 淋巴细胞的恶性疾病。我们之前已经表明,CLL 细胞的一个特征是蛋白激酶 CβII(PKCβII)的高表达和高活性,这可能通过调节 B 细胞受体结合后的信号转导来影响疾病的进展。本研究的目的是探讨刺激 CLL 细胞中 PKCβII 表达的相关因素。在这里,我们发现血管内皮生长因子(VEGF)刺激 CLL 细胞中 PKCβII 的激活可以驱动 PKCβ 基因(PRKCB1)的表达。我们发现 VEGF 对 PRKCB1 转录的这种作用与 PKCβII 蛋白的高表达平行,因此可能有助于 CLL 细胞的恶性表型。总之,本研究中的数据表明,VEGF 除了在提供生存信号方面的作用外,还在 PKCβII 的过度表达中发挥作用,PKCβII 是 CLL 中具有特定病理生理作用的一种酶。

相似文献

1
Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells.血管内皮生长因子刺激慢性淋巴细胞白血病细胞中蛋白激酶 CβII 的表达。
Blood. 2010 Jun 3;115(22):4447-54. doi: 10.1182/blood-2009-06-229872. Epub 2010 Feb 17.
2
B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII.慢性淋巴细胞白血病细胞中的B细胞受体信号传导由过度表达的活性蛋白激酶CβII调节。
Blood. 2007 Feb 1;109(3):1193-201. doi: 10.1182/blood-2006-03-012021. Epub 2006 Sep 26.
3
Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells.血管内皮生长因子诱导慢性淋巴细胞白血病细胞蛋白激酶 CβII 表达的转录机制。
Sci Rep. 2017 Feb 24;7:43228. doi: 10.1038/srep43228.
4
Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications.Aiolos 表达失调与慢性淋巴细胞白血病的表观遗传修饰有关。
Blood. 2011 Feb 10;117(6):1917-27. doi: 10.1182/blood-2010-09-307140. Epub 2010 Dec 7.
5
VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.慢性淋巴细胞白血病(CLL)B细胞上的血管内皮生长因子(VEGF)受体与信号转导和转录激活因子1及3相互作用:对凋亡抗性的影响
Leukemia. 2005 Apr;19(4):513-23. doi: 10.1038/sj.leu.2403667.
6
Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII.蛋白激酶CβII对主动脉血管平滑肌细胞中PI3K和MAPK依赖性趋化作用的调节
Circ Res. 2005 Feb 4;96(2):197-206. doi: 10.1161/01.RES.0000152966.88353.9d. Epub 2004 Dec 9.
7
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.在慢性淋巴细胞白血病细胞中,功能性1-磷酸鞘氨醇受体-1的表达受B细胞受体信号传导的抑制,而通过抑制PI3激酶δ可使其表达增加,但抑制脾酪氨酸激酶(SYK)或布鲁顿酪氨酸激酶(BTK)则不会增加其表达。
J Immunol. 2015 Mar 1;194(5):2439-46. doi: 10.4049/jimmunol.1402304. Epub 2015 Jan 28.
8
Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.骨髓基质诱导的慢性淋巴细胞白血病细胞对三氧化二砷的耐药性涉及Mcl-1上调,并且通过抑制PI3Kδ或PKCβ信号通路可克服这种耐药性。
Oncotarget. 2015 Dec 29;6(42):44832-48. doi: 10.18632/oncotarget.6265.
9
Central role of PKCbeta in neointimal expansion triggered by acute arterial injury.蛋白激酶Cβ在急性动脉损伤引发的新生内膜增生中的核心作用。
Circ Res. 2005 Mar 4;96(4):476-83. doi: 10.1161/01.RES.0000156903.37007.d1. Epub 2005 Jan 20.
10
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.酪氨酸激酶Syk通过蛋白激酶Cδ(PKCδ)和蛋白酶体依赖性的Mcl-1表达调控,调节慢性淋巴细胞白血病B细胞的存活。
Oncogene. 2009 Sep 17;28(37):3261-73. doi: 10.1038/onc.2009.179. Epub 2009 Jul 6.

引用本文的文献

1
Signal Transduction in Immune Cells and Protein Kinases.免疫细胞和蛋白激酶中的信号转导。
Adv Exp Med Biol. 2021;1275:133-149. doi: 10.1007/978-3-030-49844-3_5.
2
Molecular identification of protein kinase C beta in Alzheimer's disease.阿尔茨海默病中蛋白激酶 Cβ的分子鉴定。
Aging (Albany NY). 2020 Nov 7;12(21):21798-21808. doi: 10.18632/aging.103994.
3
A novel transgenic mouse strain expressing PKCβII demonstrates expansion of B1 and marginal zone B cell populations.一种新型表达 PKCβII 的转基因小鼠品系可扩增 B1 和边缘区 B 细胞群体。
Sci Rep. 2020 Aug 4;10(1):13156. doi: 10.1038/s41598-020-70191-y.
4
Dietary fat/cholesterol-sensitive PKCβ-RB signaling: Potential role in NASH/HCC axis.饮食脂肪/胆固醇敏感的蛋白激酶Cβ-调节亚基信号传导:在非酒精性脂肪性肝炎/肝癌轴中的潜在作用。
Oncotarget. 2017 May 15;8(43):73757-73765. doi: 10.18632/oncotarget.17890. eCollection 2017 Sep 26.
5
Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells.血管内皮生长因子诱导慢性淋巴细胞白血病细胞蛋白激酶 CβII 表达的转录机制。
Sci Rep. 2017 Feb 24;7:43228. doi: 10.1038/srep43228.
6
Protein kinase C in cellular transformation: a valid target for therapy?细胞转化中的蛋白激酶C:一个有效的治疗靶点?
Biochem Soc Trans. 2014 Dec;42(6):1556-62. doi: 10.1042/BST20140255.
7
Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types?慢性淋巴细胞白血病细胞中的B细胞受体信号传导与其他B细胞类型中的B细胞受体信号传导有差异吗?
Scientifica (Cairo). 2014;2014:208928. doi: 10.1155/2014/208928. Epub 2014 Jul 2.
8
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.氟达拉滨和贝伐珠单抗治疗复发的慢性淋巴细胞白血病患者。
Cancer. 2014 Nov 15;120(22):3494-501. doi: 10.1002/cncr.28910. Epub 2014 Jul 15.
9
A case of comorbid myxoma and chronic lymphocytic leukemia: not just a coincidence?黏液瘤与慢性淋巴细胞白血病合并病例:这仅仅是巧合吗?
Case Rep Oncol Med. 2014;2014:142746. doi: 10.1155/2014/142746. Epub 2014 Apr 29.
10
Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.蛋白激酶 C(PKC)作为慢性淋巴细胞白血病的药物靶点。
Med Oncol. 2013 Dec;30(4):757. doi: 10.1007/s12032-013-0757-7. Epub 2013 Oct 31.